Renal Cell Carcinoma, Thyroid Neoplasms
Lenvatinib is used to treat certain types of cancer, including thyroid cancer, which affects the thyroid gland in the neck, and renal cell carcinoma, which is a type of kidney cancer. It helps slow down the growth and spread of tumors.
Lenvatinib works by blocking proteins that help cancer cells grow and spread. This action slows down tumor growth and can even shrink tumors, making it harder for the cancer to progress.
Lenvatinib is usually taken as a capsule once daily, with or without food. The typical starting dose for adults is 24 mg per day, but your doctor may adjust this based on your response and any side effects.
Common side effects of Lenvatinib include high blood pressure, which is when the force of blood against artery walls is too high, fatigue, which means feeling very tired, and diarrhea, which is frequent loose or watery stools.
Lenvatinib can increase the risk of high blood pressure, liver problems, and heart issues. It should not be taken by people with severe liver impairment, which means the liver is not working well. Always follow your doctor's advice and report any unusual symptoms.
US(FDA), UK(BNF)
NO
NO
Kinase Inhibitor
NO
Lenvatinib can interact with medications that affect liver enzymes, such as CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin), altering its effectiveness. It may also interact with other cancer treatments, anticoagulants (like warfarin), and antihypertensive drugs, increasing the risk of bleeding or affecting blood pressure. Always inform your doctor of all medications being taken.